To more clarify the impact of osimertinib on the effectiveness of subsequent atezolizumab treatment, we extracted a subgroup including 41 patients harboring nonsquamous NSCLC with EGFR mutations (Supplementary Table S3). Here, EGFR is linked to non-small cell lung carcinoma.